Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8411405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

  1992cited by this paper
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

  1992cited by this paper
• Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.

  1991cited by this paper
• Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.

  1991cited by this paper
• Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

  1990cited by this paper
• Interleukin-2 therapy of human cancer: potential benefits versus toxicity.

  1989cited by this paper
• Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

  1989cited by this paper
• Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

  1989cited by this paper
• Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

  1989cited by this paper
• Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

  1988cited by this paper
• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  1988cited by this paper
• Biologic response modifiers in the therapy of metastatic renal cell carcinoma.

  1988cited by this paper
• Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

  1988cited by this paper
• Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas.

  1987cited by this paper
• Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

  1986cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches.

  1983cited by this paper
• Renal cell carcinoma: antitumor effects of leukocyte interferon.

  1983cited by this paper
• The treatment of renal cell carcinoma with human leukocyte alpha-interferon.

  1983cited by this paper

• Mesoporous Silica: A Promising Adjuvant for Cancer Vaccines.

  2026cites this paper
• The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

  2025cites this paper
• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)

  2010cites this paper
• Enhancing adoptive immunotherapy of cancer

  2010cites this paper
• Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma.

  2008cites this paper
• Pretreatment with Interferon-α2a Modulates Perioperative Immunodysfunction in Patients with Renal Cell Carcinoma

  2008cites this paper
• A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

  2007cites this paper
• Novel treatments for metastatic renal cell carcinoma.

  2005cites this paper
• The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma

  2005cites this paper
• Lymphocyte therapy of renal cell carcinoma

  2005cites this paper
• Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.

  2005cites this paper
• Cancer Treatment and Research

  2005cites this paper
• Growth factors and renal cancer: characterization and therapeutic implications

  2004cites this paper
• Application of IL-2 and other cytokines in renal cancer

  2004cites this paper
• Tumor-Infiltrating Lymphocytes and Interleukin-2: Dose and Schedules of Administration in the Treatment of Metastatic Cancer

  2004cites this paper
• [Active immunotherapy in the treatment of haematological neoplasias].

  2004cites this paper
• Current treatment of renal cell carcinoma.

  2004cites this paper
• Cell, gene and vaccine based strategies in kidney cancer.

  2003cites this paper
• Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of cytokines.

  2003cites this paper
• Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

  2003cites this paper
• The IFNs have been found to produce a large array of molecular and cellular actions of potential relevance to their use in cancer

  2002cites this paper
• Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.

  2002cites this paper
• Cancer immunotherapy: the interferon-alpha experience.

  2002cites this paper
• Immunotherapy of urologic tumors: principles and progress.

  2002cites this paper
• T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1.

  2001cites this paper
• Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature

  2001cites this paper
• Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer

  2001cites this paper
• Vaccines in urologic malignancies

  2001cites this paper
• Cytokine therapy in renal cell cancer.

  2000cites this paper
• [Adoptive immunotherapy: evaluation and perspectives in the treatment of certain cancers].

  2000cites this paper
• Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.

  2000cites this paper
• Adoptive cellular therapy.

  2000cites this paper
• Renal Cell Carcinoma

  2000cites this paper
• Identification of renal-cell-carcinoma-related cDNA clones by suppression subtractive hybridization

  1999cites this paper
• Vaccine therapy for prostate cancer.

  1999cites this paper
• Downregulation of TNF receptor-associated protein-2/p97 in renal cell carcinoma.

  1999cites this paper
• Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

  1999cites this paper
• Adoptive cellular immunotherapy of cancer.

  1999cites this paper
• Present achievements in the medical treatment of metastatic renal cell carcinoma.

  1999cites this paper
• Who is in control of the immune system in head and neck cancer?

  1999cites this paper
• Renal cell carcinoma: should radical nephrectomy be performed in the presence of metastatic disease?

  1999cites this paper
• The contribution of dendritic cells to immune responses against urological cancers.

  1998cites this paper
• Adenovirus‐Mediated Interleukin‐2 Production by Tumors Induces Growth of Cytotoxic Tumor‐Infiltrating Lymphocytes Against Human Renal Cell Carcinoma

  1998cites this paper
• Relevance of the immune system in human urological malignancies: prospective for future clinical treatments.

  1998cites this paper
• Minimal recruitment and activation of dendritic cells within renal cell carcinoma.

  1998cites this paper
• Use of cellular and cytokine adjuvants in the immunotherapy of cancer

  1998cites this paper
• The role of adoptive immunotherapy in solid cancers.

  1997cites this paper
• Tumor Localization by Tumor Infiltrating Lymphocytes Labeled with Indium-111 in Patients With Metastatic Renal Cell Carcinoma, Melanoma, and Colorectal Cancer

  1997cites this paper
• New Advances in Interferon Therapy of Cancer.

  1997cites this paper
• Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.

  1997cites this paper
• Dendritic cells and cancer: progress toward a new cellular therapy.

  1997cites this paper
• Natural history and therapy of metastatic renal cell carcinoma

  1997cites this paper
• Immunotherapy and gene therapy for renal cell carcinoma.

  1997cites this paper
• Characterization of Tumor‐Infiltrating Lymphocytes Derived from Human Tumors for Use as Adoptive Immunotherapy of Cancer

  1997cites this paper
• Carcinoma renal avanzado: tratamiento con interferón alfa-2a.

  1997cites this paper
• Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy

  1997cites this paper
• Renal cell carcinoma in children: the Detroit experience.

  1996cites this paper
• Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery.

  1996cites this paper
• Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

  1996cites this paper
• Immunotherapy and Gene Therapy for Genitourinary Malignancies

  1996cites this paper
• Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.

  1996cites this paper
• Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.

  1996cites this paper
• Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

  1996cites this paper
• Current management of renal cell carcinoma

  1996cites this paper
• Update on the Role of Immunotherapy in the Management of Kidney Cancer.

  1996cites this paper
• Immunotherapy of metastatic renal cell cancer.

  1996cites this paper
• Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.

  1995cites this paper
• Histologic characteristics of residual renal-cell carcinoma following interferon-alpha-based therapy - correlation with clinical-parameters.

  1995cites this paper
• Helper T Cells Infiltrating Human Renal Cell Carcinomas Have the Phenotype of Activated Memory‐Like T Lymphocytes

  1995cites this paper
• A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.

  1994cites this paper
• Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.

  1994cites this paper
• Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.

  1993cites this paper